Thus, they may be used as an adjunct to insulin and ameliorate glycemic control in diabetes.14 FDA approved dapagliflozin, canagliflozin, ertugliflozin, recently bexagliflozin and empagliflozin (drugs of SGLT2 inhibitors class) for patients with type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.